Navigation Links
New Study Shows Meganuclease-Driven Targeted Integration Using Cellectis bioresearch's cGPS® CHO-K1 Kit to be Highly Efficient for Drug Discovery
Date:7/19/2010

PARIS, July 19 /PRNewswire-FirstCall/ -- Cellectis bioresearch, a specialist in genome customization and a subsidiary of Cellectis (Alternext: ALCLS), today announced the publication of a scientific study describing a novel method, based on meganuclease-driven targeted integration, for the generation of stable cell lines compatible with high throughput screening (HTS)(1). The study demonstrated Cellectis bioresearch's technology to be faster, more reliable and efficient in deriving cell-based assays for HTS studies than classical methods. The study has been published online by Journal of Biomolecular Screening http://jbx.sagepub.com/cgi/content/abstract/1087057110375115v1.

The development of cell-based assays for HTS approaches is important to screen molecules on pharmaceutical targets and often requires the generation of stable cell lines. However, these cell lines are essentially created by random integration of a gene of interest (GOI) with no control over the level and stability of gene expression. In this study, scientists from the Servier Research institute used Cellectis bioresearch's cellular Genome Positioning System, or cGPS®, in CHO-K1 cells, to accomplish targeted integration of different GOIs. Five different GOIs representing 3 major drug target classes were stably integrated at the same locus in cGPS® CHO-K1 cells. Characterization of the targeted clones revealed that the cGPS® CHO-K1 system was more rapid (2-week protocol), efficient (all selected clones expressed the GOI), reproducible (GOI expression level variation of 12% maximum), and stable over time (no change in GOI expression after 23 weeks of culture) than classical random integration.

"Achieving a physiological level of expression compatible with the relevant functional assay is important in testing pharmaceutical targets", explained Jean Boutin, Director of the Molecular and Cellular Pharmacology Division of the SERVIER Research Institute. "We found that proteins expressed in the cGPS® CHO-K1 cells are biologically active and have enzymatic constants, localization and function close to the published values of their wild-type endogenous counterparts. This fast and robust method opens the door for creating large collections of cell lines expressing therapeutically relevant GOIs, enhancing the productivity of HTS".

About Cellectis bioresearch

Cellectis bioresearch was incorporated as a subsidiary of Cellectis SA (Alternext: ALCLS) in June 2008. It provides life science researchers with ready-to-use research tools for genome customization.  These tools, based on meganucleases, enable the customization of cells with optimized features for drug discovery, protein production and gene function study.

More information at www.cellectis-bioresearch.com

About Cellectis

Cellectis is a pioneer in the field of genome engineering. The company designs and markets innovative tools -meganucleases. These molecular scissors enable targeted modifications to DNA, with applications in the research, biomanufacturing, agrobiotechnology and therapeutic sectors.

To date, Cellectis has formed over 20 academic research partnerships and has established more than 50 agreements with pharmaceutical laboratories, seed producers and biotech companies across the world. The company holds exclusive rights to a portfolio of over 260 patents granted or pending.

Since 2007, Cellectis has been listed on the NYSE-Euronext Alternext market (code : ALCLS) in Paris and has secured over euro 70 million in funding since inception.

More information at www.cellectis.com

Disclaimer

This press release and the information contained herein do not constitute an offer to sell or subscribe, or a solicitation of an offer to buy or subscribe, shares in Cellectis in any country. This press release contains forward-looking statements that relate to the Company's objectives. Such forward-looking statements are based on the current expectations and assumptions of the Company's management only and involve risk and uncertainties. Potential risks and uncertainties include, without limitation, whether the Company will be successful in implementing its strategies, whether there will be continued growth in the relevant market and demand for the Company's products, new products or technological developments introduced by competitors, and risks associated with managing growth. Unfavorable developments in connection with these and other risks and uncertainties described, in particular, in the Company's prospectus prepared in connection with its IPO and on which the French Autorite des marches financiers ("AMF") granted its visa n° 07-023 on January 22, 2007, could cause the Company to fail to achieve the objectives expressed by the forward-looking statements above.

(1) JP Cabaniols et al. Meganuclease-driven targeted integration in CHO-K1 cells fort he fast generation of HTS compatible cell-based assays. Journal of Biomolecular Screening 2010, doi:10.1177/1087057110375115


'/>"/>
SOURCE Cellectis bioresearch
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Phase 3 Open-Label Study Comparing Tapentadol Extended Release Tablets to Oxycodone Controlled Release Tablets Published by Pain Practice
2. Worlds Largest Study on Insulin Therapy Completes Recruitment With 60,000 Patients
3. Study of Long-Term Efficacy and Safety of New PyratineXR™ Moisturizing Lotion Featured in Journal of Drugs in Dermatology
4. 12-Month Study Reports 90% Success Rate for AMS MiniArc Single-Incision Sling
5. New Study Reveals Proprietary Saw Palmetto Extract (SPET-085) Supplement Can Effectively Inhibit the Enzyme Linked to Benign Prostatic Hyperplasia (BPH)
6. Dune Medical Devices Announces Positive Interim Results From EU MarginProbe™ Study Presented at German Breast Cancer Society Meeting
7. Drug Study Shows Improvement in Major Orthopedic Surgery Care
8. Enrollment Underway in CLARITY-AF Study to Compare Efficacy, Safety and Efficiency of Two Catheter Ablation Technologies
9. Nile Therapeutics Completes Dosing of Phase II Study
10. Adeona Completes Equity Financing and Provides Alzheimers Disease Clinical Study Update
11. Sangamo BioSciences Announces Nature Biotechnology Study Demonstrating the Use of Zinc Finger Nucleases to Generate HIV Resistant Human Stem Cells
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/2/2017)... Aug. 2, 2017  Life Flight Network and PeaceHealth Oregon ... improves patient care and operational efficiency for patients at hospitals ... , Cottage Grove , and ... PeaceHealth and Life Flight Network work collaboratively to move patients ... or when a time sensitive emergency exists. ...
(Date:8/1/2017)... , Aug. 1, 2017   CerSci Therapeutics , ... Dallas, Texas , has received notice from the ... Institutes of Health (NIH) that it has been awarded ... totaling over $650,000 in 2017 with an additional $1,000,000 ... Investigational New Drug application of their lead non-opioid drug ...
(Date:7/31/2017)... Three Tru-D SmartUVC robots have arrived at Brian ... . Tru-D, short for "Total Room Ultraviolet Disinfection," is a 5-foot-5 germ-killing ... services (ES) professional cleans the area with traditional cleaning protocols. ... Tru-D fights germs at Army ... "Although the BAACH has a very low infection ...
Breaking Medicine Technology:
(Date:8/17/2017)... ... August 17, 2017 , ... Aeroflow Healthcare today ... recognizing America’s fastest growing private companies. Inc. magazine ranked Aeroflow Healthcare #2450 on ... , The Inc. 5000 represents the most comprehensive study of American ...
(Date:8/17/2017)... ... August 17, 2017 , ... SeQuel Response announced ... multichannel growth agency among the fastest-growing private companies in the U.S., putting it in ... companies that have applied to the Inc. 5000 over the years, only ...
(Date:8/17/2017)... ... August 17, 2017 , ... With the introduction of new ... a number of changes to the smartwatch market. As of June 2017, nearly nine ... from the six months prior. Additionally, according to latest WEAR Report Industry Overview and ...
(Date:8/17/2017)... ... August 17, 2017 , ... Inc. Magazine Unveils 36th Annual List ... with Three-Year Sales Growth of 3,004.8% , NEW YORK, August 16, 2017 – Inc. ... most prestigious ranking of the nation's fastest-growing private companies. The list represents a unique ...
(Date:8/17/2017)... ... August 17, 2017 , ... Advice Media, the industry leader in digital marketing for medical practices, ... and has been included in the Inc. 5000 for the second time in two years. ... in the Inc. 5000 rankings for the second year in a row. It’s extremely difficult ...
Breaking Medicine News(10 mins):